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Measuring intracellular metabolism has increasingly led to
important insights in biomedical research. 13C tracer analysis,
although less information-rich than quantitative 13C flux
analysis that requires computational data integration, has been
established as a time-efficient method to unravel relative
pathway activities, qualitative changes in pathway
contributions, and nutrient contributions. Here, we review
selected key issues in interpreting 13C metabolite labeling
patterns, with the goal of drawing accurate conclusions from
steady state and dynamic stable isotopic tracer experiments.
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Introduction
Investigating cellular metabolism has a long-standing
history in various research areas such as biochemistry,
biotechnology and cellular physiology. A widely applica-
ble toolbox to quantitatively measure intracellular me-
tabolism has been developed in the context of
biochemical engineering [1]. In light of the emerging
realization that altered cellular metabolism contributes to
many diseases including cancer, metabolic syndromes,
and neurodegenerative disorders, these approaches are
being increasingly applied to address biomedical research
questions [2–8,9!].
Cellular metabolism can be characterized by many pa-
rameters including nutrient uptake and metabolite secre-
tion rates, intracellular metabolite levels, intracellular
metabolic rates (fluxes), nutrient contributions to metab-
olite and macromolecule synthesis, and pathway activities
[2,3,9!,10–12].
Metabolomics, which provides absolute or relative intra-
cellular or extracellular metabolite levels, is a broad and
sensitive method to detect differences in metabolic states
between conditions [13–16]. Changes in intracellular
metabolite levels indicate an altered activity of the con-
nected consuming or producing reactions (e.g. enzymatic,
non-enzymatic, or transport reactions) [17!,18!,19–21].
However, concentration changes do not readily allow
conclusions on metabolic rates (fluxes), or the direction
of the flux changes, since an increase in metabolite
concentration can both be indicative of increased activity
of metabolite producing enzymes, but also decreased
activity of metabolite consuming enzymes.
In combination with growth rates (which provide global
information on metabolic fluxes to biomass production),
metabolite uptake/secretion rates provide a macroscopic
picture of overall metabolism. For instance, measuring
the rate of glucose depletion from the media reports the
rate of glucose used by cells in a culture system. However,
these data alone are insufficient to reveal intracellular
fluxes throughout the different metabolic pathways.
To examine intracellular fluxes (metabolite amount con-
verted/cell/time), heavy isotope (most frequently 13C)
labeled nutrients (tracers) are commonly utilized [22–
29]. In formal 13C flux analysis, labeling patterns in
intracellular metabolites resulting from metabolizing a
13C labeled nutrient, cellular uptake and secretion rates,
and prior knowledge of the biochemical reaction network
are combined to computationally estimate metabolic
fluxes [11,30!!,31–33,34!!]. In practice, resolving meta-
bolic fluxes from measured data can be time and data-
intensive. In many cases, however, direct interpretation
of 13C labeling patterns (without formal 13C flux analysis)
is sufficient to provide information on relative pathway
activities, qualitative changes in pathway contributions
via alternative metabolic routes, and nutrient contribu-
tion to the production of different metabolites. We refer
to this direct interpretation of 13C labeling patterns as 13C
tracer analysis. Here, we discuss selected important
aspects to consider when performing 13C tracer analysis
to ensure correct data interpretation and to increase the
insight obtained by stable isotopic tracer experiments.
Metabolic steady state versus isotopic steady
state
Metabolic steady state requires that both, intracellular
metabolite levels and intracellular metabolic fluxes of a
cell or a cell population are constant (Figure 1a) [35].
Controlled culture systems that ensure metabolic steady
state are continuous cultures (known as chemostats), where
cell number and nutrient concentrations are maintained
constant throughout the experiment [36]. More commonly,
experiments are performed at pseudo-steady state, where
changes in metabolite concentrations and fluxes are mini-
mal on the timescale over which the measurement is being
made. In adherent mammalian cell culture, perfusion
bioreactors and nutrostats [37,38], where nutrient concen-
trations but not cell number are constant over time, are
closest to a chemostat. In conventional monolayer culture,
the exponential growth phase is often assumed to reflect
metabolic pseudo-steady state, because cells in the culture
steadily divide at their maximal condition specific rate,
given that nutrient supply does not become limiting [39].
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So long as biological changes (e.g. differentiation) occur
slowly relative to the timescale of metabolic measurement,
non-proliferating cells are generally also in metabolic pseu-
do-steady state. This can be verified by time resolved
measurements of metabolic parameters  of interest [40]. In
case the biological system is not in metabolic pseudo-steady
state, for example, following acute signaling events or nutri-
ent modulations, tracer experiments can still provide quali-
tative and quantitative information on metabolic pathway
fluxes, but interpretation of non-steady state data require
different approaches [30!!,41–43] than the here discussed
13C tracer analysis at metabolic pseudo-steady state.
While metabolic steady state characterizes the state of
metabolism, isotopic steady state characterizes the en-
richment of a stable isotopic tracer in metabolites. When a
13C labeled substrate is added and subsequently metab-
olized, the metabolites will become with time increas-
ingly enriched for 13C until the point where the 13C
enrichment is stable over time (Figure 1b). From a
practical perspective, isotopic steady state is reached
when 13C enrichment into a given metabolite is stable
over time relative to experimental error and/or the desired
measurement accuracy. These enrichment dynamics dif-
fer depending on the analyzed metabolite and the tracer
employed, since the time required to reach isotopic
steady state depends on both the fluxes (i.e. rate of
conversion) from the nutrient to that metabolite, and
the pool sizes of that metabolite and all intermediate
metabolites. For example, upon labeling with 13C-glu-
cose, isotopic steady state in glycolytic intermediates
typically occurs within minutes, whereas for tricarboxylic
acid (TCA) cycle intermediates it may take several hours.
For many amino acids that are both produced by the cell
and are supplemented in the media isotopic steady state
may never be achieved in standard monolayer culture,
due to constant and rapid exchange between the intra-
cellular and the extracellular amino acid pools. In such a
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Labeling basics. (a) Time dependent metabolic changes: Metabolism reaches a metabolic steady state when the parameters of interest (e.g.
glucose uptake rate) are constant over time. (b) Time dependent labeling changes: Upon addition of an isotopically labeled carbon source, the
isotopic enrichment will increase in the metabolites until the steady state enrichment is reached. (c) Mass distribution vector (MDV) (also known as
mass isotopomer distribution (MID) vector): Labeling patterns are MDVs that consist of the fractional abundance of each isotopologue (also known
as mass isotopomer). M denotes mass of the unlabeled metabolite. (d) Cellular compartmentalization: Most labeling pattern detection methods
cannot resolve different cellular compartments, thus the whole cell average labeling pattern is measured.
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situation, qualitative tracer analysis can easily be mislead-
ing, and quantitative, formal approaches are required (e.g.
[44!]).
Key aspects:
! Proper interpretation of labeling data depends on prior
assessment of whether the system is at metabolic
pseudo-steady state. If so, interpretation of tracer data
is most simple if labeling is allowed to proceed also to
isotopic steady-state.
! The time to reach isotopic steady state depends both
on the tracer being employed and the metabolites
being analyzed.
! Many amino acids are freely exchanged between
intracellular and extracellular pools. This can prevent
labeling from reaching isotopic steady state and any
intracellular metabolite pool that is in rapid exchange
with a larger extracellular pool is subject to this
complication.
Labeling patterns
The term ‘labeling pattern’ refers to a mass distribution
vector (MDV) (they are also frequently called mass iso-
topomer distribution (MID) vectors) (Figure 1c). The
shift in mass of a metabolite occurs due to the incorpo-
ration of isotopes. Metabolites that only differ in the
isotope composition are isotopologues (they are frequent-
ly also called mass isotopomers). MDVs describe the
fractional abundance of each isotopologue normalized
to the sum of all possible isotopologues. A metabolite
with n carbon atoms can have 0 to n of its carbon atoms
labeled with 13C, resulting in isotopologues that increase
in mass (M) from M+0 (all carbons unlabeled i.e. 12C) to
M+n (all carbons labeled i.e. 13C). Hence, the MDV
represents the relative abundances of M+0 to M+n iso-
topologues for one particular metabolite (Figure 1c).
Consequently, the sum of all fractions from M+0 to
M+n is 100% or 1. Note that in respect to 13C each
isotopologue has
n
k
! "
isotopomers (same isotope com-
position but different position of the isotope within the
metabolite), when n denotes the number of carbons in a
metabolite and k the number of carbons that are 13C
(Figure 1c). Isotopomers can only be resolved using a
detection method that can assign a specific position to a
13C within a molecule (e.g. nuclear magnetic resonance
spectroscopy [45], mass spectrometry analysis of multiple
fragments [46] or in specific cases tandem mass spectrom-
etry [47,48]). Although information on the position of a the
13C label can increase the information content of labeling
data, the MDV is typically sufficient to draw conclusions on
nutrient contributions, and also often regarding pathway
activities. Notably, while we will discuss 13C tracer analy-
sis, the above-described MDVs can be also applied to other
stable isotopes including 15N and 2H.
To apply MDVs to assess nutrient contributions and
pathway activities, it is important to first correct for the
presence of naturally occurring isotopes, for example, 13C
(1.07% natural abundance (na)), 15N (0.368% na), 2H
(0.0115% na), 17O (0.038% na), 18O (0.205% na), 29Si
(4.6832% na), or 30Si (3.0872% na) [49,50!,51!!]. For ex-
ample, glutamate and a-ketoglutarate, which are normally
in complete exchange and share the same carbon back-
bone, should accordingly have matching MDVs. Yet,
since they differ in their molecular formula, uncorrected
MDVs of glutamate and a-ketoglutarate will not match
because of the natural occurring isotopes in N, H, and O.
For analytical methods that require metabolite derivati-
zation to enable chromatographic separation (e.g. gas
chromatography–mass spectrometry), the chemical mod-
ification adds additional C, H, N, O, and Si atoms to the
metabolites [22,52]. Hence, the natural labeling of all
atoms in the metabolite and the derivatization agent
needs to be taken into account when performing data
correction. For analysis of underivatized metabolites
(e.g. by liquid chromatography–mass spectrometry), nat-
urally occurring 13C has a much greater effect than other
natural isotopes, and it is minimally imperative to correct
for it.
A general applicable correction matrix can be formulated
based on Eqn. (1).
I0
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I2
. . .
In
. . .
Inþu
0BBBBBBBBBBB@
1CCCCCCCCCCCA
¼
LM00 0 0 . . . 0
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0 0 . . . 0
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. . . . . . . . . . . . . . .
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. . . . . . . . . . . . . . .
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%
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Here, the vector I denotes the fractional abundances of
the measured metabolite ions. M represents the MDV
corrected for naturally occurring isotopes. n denotes the
number of carbon atoms that are present in the analyzed
metabolite ion and are subject to isotope labeling. u
denotes additional measured ion abundances beyond n
originating from natural isotopes in the metabolite or the
derivatization. L denotes the correction matrix and the
columns LMk denote the theoretical natural MDV when k
(0 to n) carbons are 13C. The correction matrix L can be
calculated based on the sum formula of the metabolite ion
under consideration of natural isotope abundances
[49,53,54]. To solve the linear equation system at least
n+1 abundances have to be measured. If more than n+1
abundances are considered, this results in an overdeter-
mined system and provides a more robust solution. Tools
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for quickly converting raw into corrected MDVs are
available [55,56].
When using analytical approaches involving selected ion
monitoring (SIM) or selected reaction monitoring (SRM)
mass spectrometry, it is important to consider upfront the
potential role of naturally occurring isotopes when setting
the selected mass range [50!]. In cases involving deriva-
tization with Si-containing reagents, inclusion of these
higher mass ranges may be important and the required
mass range can be estimated based on multinomial ex-
pansion (typically a shift of up to 4 amu beyond the mass
of the fully labeled metabolite should be considered).
Comparison between labeled and unlabeled samples is
sufficient to determine whether an observed mass shift
truly reflects labeling (as opposed to merely natural
isotope abundance). It is not appropriate, however, to
subtract the MDV of an unlabeled sample from the
labeled sample. Typically, the main natural abundance
peak in the unlabeled sample will be M+1, whereas in
labeled samples natural abundance results in peaks at
higher masses.
The natural occurring isotopes can be also used to validate
the applied mass spectrometry method for its accuracy to
measure isotopologue distributions [22]. Specifically, me-
tabolites can be extracted from cells fed with naturally
labeled nutrients (commonly referred to as unlabeled
nutrients) and consequently the measured MDV of these
metabolites should accurately (absolute error <1.5%) re-
flect the theoretical distribution of natural occurring iso-
topes. With this validation the applied mass spectrometry
method can be improved or metabolites for which the
isotopologue distribution is measured with poor accuracy
can be excludes. It is important to be aware of the extent of
error in MDV measurements and to interpret resulting
labeling data accordingly. Random error in MDV measure-
ment is often significant for metabolites that are low
abundance (i.e. measurement signal close to noise). Sys-
tematic error in MDV measurement is more serious and
can reflect metabolite misannotations or overlaps of the
measured metabolite ions with same mass ions from sam-
ple matrix components. In case the accuracy to measure
isotopologue distributions is validated, data variability can
be a subject of the experimental procedure (e.g. inade-
quate metabolism quenching) or the biological system (e.g.
rapid metabolic shifts or a continuous metabolic drift).
Key aspects:
! Correction for natural abundance facilitates proper
interpretation of labeling data.
! Subtracting the measured MDV of an unlabeled
metabolite from the measured MDV of the labeled
metabolite is not a valid method to correct for natural
abundance.
! Labeling patterns must be interpreted in light of the
experimental error in MDV measurements of the
chosen analytical approach. Measurement error will
typically be higher for low abundance compounds.
! In case measurement inaccuracy can be excluded, data
variability can result from the experimental procedure
or the biological system.
Cellular compartments
Eukaryotic cells have organelles such as mitochondria and
peroxisomes, and these organelles result in intracellular
compartmentalization of metabolites and metabolic reac-
tions. Many metabolites are present in multiple intracel-
lular compartments and even spatial distribution within a
compartment might occur. This adds a layer of complexi-
ty to understanding metabolism. Only the average label-
ing pattern and metabolite levels from all compartments
within a cell can be measured using most current tech-
niques (Figure 1d) [57,58].
Depending on the metabolite of interest, compartment-
specific labeling patterns in some cases can be inferred
from labeling of metabolites that are produced exclusive-
ly in one compartment (Figure 1d). For example, pyru-
vate is found both in the cytosol and in the mitochondria.
Lactate and alanine are both directly produced from
pyruvate. Lactate dehydrogenase, the enzyme which
interconverts pyruvate and lactate, is a strictly cytosolic
enzyme [59], an assumption in agreement with the ob-
servation that the deletion of the mitochondrial pyruvate
carrier does not affect lactate production [60,61]. The
finding that mitochondrial pyruvate carrier deletion dras-
tically affects alanine production [60,61] supports that
alanine is produced extensively from mitochondrial py-
ruvate [62]. Thus, under experimental conditions in
which neither exogenous alanine nor lactate is available
to cells, lactate labeling likely reflects the labeling pattern
of cytosolic pyruvate, while alanine labeling better
reflects the labeling pattern of mitochondrial pyruvate.
Additionally, engineered compartment-specific produc-
tion of metabolites in cells can also be used to provide
compartment specific information. For example, labeling
of NADPH in the mitochondria and the cytosol was
determined by compartmentalized transfer of deuterium
to the metabolite 2-hydroxyglutarate (2-HG) [63!]. Spe-
cifically, transient expression of either mutant isocitrate
dehydrogenase 1 or 2 results in compartment specific
production of 2-HG that utilizes NADPH available in
that location. This approach, and a similar approach but
without engineered compartment specific production of
2-HG was used to infer compartmentalized serine —
glycine interconversion [63!,64!].
Key aspects:
! In most cases cell average labeling patterns are measured.
Because many metabolites are present in more than one
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subcellular compartment, this can affect the extent and
pattern of the metabolite labeling observed.
Steady state labeling
MDVs describe the relative fractions of isotopologues
within a metabolite. At isotopic steady state, and in the
absence of compartment-specific labeling patterns,
MDVs are independent of metabolite levels. Therefore,
metabolites that are in complete exchange such as gluta-
mate and a-ketoglutarate have identical MDVs even
though their intracellular levels are very different [65–
67] (Figure 2a). Consequently, any further analysis of
relative pathway activities, qualitative changes in path-
way contributions, or nutrient contributions based on
isotopic steady state labeling data only requires MDVs
and is independent of the metabolite levels. Notably, this
simplifying assumption breaks down when compartmen-
tation is significant and results in compartment-specific
labeling patterns (see section above).
Nutrient contribution
To determine which fraction of a metabolite’s carbon is
produced from a certain nutrient the fractional contribution
(FC) using the fully 13C-labeled nutrient can be calculated
based on Eqn. (2). Using positionally labeled nutrients for
this analysis is not advised because positionally labeled
tracers will not only reflect changes in the FC but also
differential pathway usage. For example, the FCfrom glucose
in pyruvate calculated from a 1-13C1-glucose tracer can be
altered between conditions because of a reduction in the
fraction of pyruvate produced from glucose or because the
forward flux through the oxidative and non-oxidative pen-
tose phosphate pathway is increased, leading to the incor-
poration of the 13C labeled carbon into CO2.
FC ¼
Pn
i¼0 i % mi
n %Pni¼0 mi (2)
Here n is the number of C atoms in the metabolite, i
denotes the isotopologues, and m the abundance of an
isotopologue. Alternatively, FC can be directly calculated
from the MDV by Eqn. (3), which takes advantage of the
fact that the sum of all fractions from M+0 to M+n is
already normalized to 1.
FC ¼
Pn
i¼0 i % si
n
(3)
Here s is the relative fraction of the isotopologues.
If only two carbon sources (e.g. glucose and glutamine)
contribute to the formation of a metabolite, the sum of
FCfrom glutamine and FCfrom glucose will be 100% or 1 for this
metabolite (Figure 2b). Thus, the relative contributions
of carbon sources to a metabolite can be determined from
FCs. As an example, this approach was applied to reveal a
switch from glucose to glutamine-derived tricarboxylic
acid (TCA) cycle metabolites during metformin treat-
ment [68]. For any metabolite that is subject to a carbox-
ylation reaction the FC values will be reduced due to
incorporation of unlabeled CO2 [69]. Similarly any other
incorporation of unlabeled carbon sources will also lead to
a reduced FC. For example a low FC of fatty acids from
13C6-glucose and
13C5-glutamine in hypoxia was recently
used to reveal a contribution from serum acetate to fatty
acid synthesis [70].
Also isotope impurity of the tracer will reduce FC values.
Yet, for standard quality of tracers (e.g. 1% for 13C6-
glucose), the reduction of FC values based on isotope
impurity is marginal. For example, although in 13C6-
glucose with 1% isotope impurity only 94% of the glucose
molecules carry at each carbon position a 13C, the FC for
this 13C6-glucose is 0.99. Thus, normalizing to the FC of
the tracer has in this case little effect. However, for tracers
with higher isotope impurity a normalization to the FC of
the tracer can be useful.
Nutrient contribution indirectly provides some informa-
tion on flux: it reveals the fraction of the metabolite being
formed by the sum of all pathways leading from the
labeled nutrient to the metabolite. It does not reveal
the activity of specific pathways, nor absolute fluxes.
For example, two metabolites can have identical FC
although the net flux (Figure 2c) of the labeled nutrient
to one of the metabolites is much smaller than to the
other, but between both metabolites exists a rapid ex-
change flux. Thus, rapid exchange fluxes (Figure 2c) can
readily label metabolites although the net flux to the
metabolite might be marginal.
Key aspects:
! If the sum of the labeled nutrient contributions to a
metabolite do not sum up to 100% or 1, and the labeling
in the metabolite is in isotopic steady state, there are
additional sources that contribute to the production of
that metabolite.
! In general, nutrient contributions alone do not reveal
specific or absolute fluxes.
! Exchange fluxes can lead to labeled metabolites
although the net flux to the metabolites is marginal.
Pathway activity
Specific isotopologues do not provide per se information
on absolute fluxes, rather they allow conclusions on rela-
tive pathway activities and qualitative changes in path-
way contributions to the production of a certain
metabolite. Thereby, isotopologue patterns can indicate
the activity of alternative metabolic routes.
Relative pathway activity
Relative pathway activities can be inferred from a ratio
between two alternative and converging pathways. A 13C
194 Systems biology
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labeled tracer can be fed to the cells, which is designed to
result in different labeling patterns when converted
through either of the two alternative metabolic pathways.
Calculating a split ratio of the activity between two
alternative and converging pathways requires that the
labeling patterns of the metabolites are valid surrogates
of the two pathways, and that a converged pathway
metabolite can be measured [50!]. Consequently, the
sum of the relative activity of both alternative and con-
verging pathways is 100% or 1. In those cases where
additional information can provide the forward flux for
one of the pathways, then the forward flux of the other
pathway can be calculated based on the split ratio.
For example, the pentose phosphate pathway has both
oxidative and non-oxidative branches that connect to gly-
colysis at different locations [71!]. Under some conditions,
pentoses produced via the oxidative pathway can re-enter
glycolysis via the non-oxidative pathway, providing two
routes from glucose-6-phosphate to trioses. When 1,2-13C2-
glucose is converted through glycolysis, M+0 and M+2
pyruvate will be formed, while conversion of glucose to
pyruvate through the oxidative pentose phosphate path-
way will lead to M+0, M+1, and M+2 pyruvate. The split
ratio (relative pathway activity) between glycolysis and the
pentose phosphate pathway can be estimated based on the
above-described different labeling patterns [72,73]. Nota-
bly, the difference in pyruvate labeling is not informative as
to relative pentose phosphate pathway and glycolysis flux if
the non-oxidative pentose phosphate pathway flux is di-
rected toward pentose production, as it is the case in many
cancer cells [74,75]. A more direct measurement of oxida-
tive pentose phosphate pathway flux can be obtained from
quantifying 14CO2 production from 1-
14C1-glucose versus
6-14C1-glucose [76]. Alternatively, formal
13C flux analysis
or isotopomer analysis based on nuclear magnetic reso-
nance can be applied to determine the oxidative pentose
phosphate pathway activity from 13C-labeling data (e.g.
[77,78]).
Importantly, if a single nutrient contributes to a pathway,
then steady state labeling data are not informative as
to relative or qualitative pathway activity or flux. For
13C tracer analysis Buescher et al. 195
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Interpretation of labeling data. (a) Steady state labeling data are
independent from the metabolite levels. (b) Fractional contribution
quantifies the contribution of a labeled nutrient to the metabolite of
interest. (c) Exchange fluxes can lead to rapidly labeled metabolites
although the net flux of the nutrient to the metabolites is small. (d)
Dynamic labeling patterns are metabolite level dependent: The flux
from glutamine to glutamate is the same in condition A and B, but in
condition A the glutamate levels are greater than in condition B.
Consequently, the labeling dynamics of glutamate in condition A are
slower than in condition B although the flux from glutamine to
glutamate is the same in both conditions. (e) Relative flux activity
between two conditions can be evaluated without kinetic flux
calculations if both the labeling dynamics and all metabolite levels of
the pathway of interest are altered in the same direction.
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instance, in most cases glycolytic intermediates are la-
beled primarily from glucose and the fact that glycolytic
intermediates are labeled from glucose at steady state
does not provide any information on the magnitude of the
glycolytic flux.
Qualitative changes in pathway contribution
Qualitative changes in pathway contribution are indicative
of whether a certain pathway is used to produce a metabo-
lite. Thereby, only the labeling pattern that is indicative for
the pathway of interest is analyzed. Consequently, no
quantitative split ratio is calculated between the pathway
of interest and the alternative conversion routes, and only
qualitative information is obtained. Examples are changes
in the fractional abundance of M+5 citrate from 13C5-
glutamine to suggest reductive glutamine metabolism
[79–84], or M+3 malate from 13C6-glucose to suggest
contribution of pyruvate via pyruvate carboxylase. The
example of pyruvate carboxylase is discussed in full detail
in Box 1. Recognizing the limitations of the specific iso-
topologues to be indicative for relative pathway activities
or qualitative changes in pathway contribution is impor-
tant, and use of more than one tracer as well as investigation
of more than one metabolite labeling can increase confi-
dence in conclusions (Box 1).
Key aspects:
! Steady state labeling patterns are independent of
metabolite levels. Consequently, multiplying MDVs
with metabolite levels at isotopic steady-state (or
simply reporting the absolute magnitudes of different
labeled species) does not reliably provide information
on any metabolic changes. More reliable information is
obtained by examining the steady-state labeling
fractions themselves to infer relative or qualitative
pathway activities and nutrient contributions.
! Relative pathway activities and qualitative changes in
pathway contribution to the production of a metabolite
do not allow conclusions on absolute flux magnitudes.
! Steady state labeling patterns are information-rich for
metabolites in pathways with more than one source of
nutrient contribution or alternative metabolic routes for
nutrient contribution.
! Steady state labeling patterns for linear pathways
without alternative nutrient contributions are not
informative for pathway activity.
! If no formal split ratio of pathway contribution can be
calculated, any pathway activity inferred from steady
state labeling patterns is qualitative.
! It is important to remember that relative contributions
may change due to the increased activity of one
pathway, or the decreased activity of another pathway.
! Analysis of labeling patterns from more than one 13C
tracer can increase confidence in data interpretation.
! Analysis of labeling patterns in more than one metabo-
lite can increase confidence in data interpretation.
Dynamic labeling
Dynamic labeling is a powerful method to infer flux from
metabolite labeling data and metabolite levels
(Figure 2d) [30!!,41,51!!,85!]. During dynamic labeling,
how fast a metabolite pool becomes labeled is measured.
The underlying principle is that the greater a flux the
faster a metabolite pool becomes labeled; however, con-
sidering the size of the metabolite pool is crucial as larger
metabolite pools will take longer to be labeled than
smaller metabolite pools (Figure 2d). Thus, dynamic
labeling patterns are inherently metabolite level depen-
dent, and will also depend on the pool size and labeling
rates of upstream metabolites if the labeled intermediate
is not directly produced from the 13C tracer.
Integrating dynamic labeling data into metabolic models
has mainly been applied to microbial systems, although
other systems have been recently investigated as well
[34!!,39,86–89]. For a meaningful direct interpretation of
dynamic labeling patterns a suitable time resolution (i.e.
multiple time points that cover the labeling dynamics)
and measurement of the metabolites that are upstream of
the metabolite of interest are essential. This is required to
(a) obtain reliable curve fits and (b) determine when the
dynamic profile transitions to steady state labeling. Nota-
bly, dynamic labeling is limited by the feasible time
resolution. Therefore, low flux pathways such as gluta-
mine anaplerosis to the TCA cycle (conversion of gluta-
mine to a-ketoglutarate) are easier to correctly infer with
dynamic labeling data than high flux pathways such as
glycolysis. Additionally, the direct interpretation of dy-
namic labeling patterns (without sophisticated methods
such as non-stationary 13C flux analysis) requires that the
metabolite levels are constant over time. In practice, this
is often achieved by exchanging the medium for a period
of time with unlabeled medium before adding 13C-la-
beled media. This allows the intracellular metabolite
levels that are in rapid exchange with the medium (e.g.
lactate) to equilibrate to a medium without high levels of
these metabolites present extracellularly. Importantly,
13C tracer analysis as discussed here is only valid if the
media change does not affect the metabolic steady state.
For calculating fluxes from dynamic labeling data two
cases have to be considered. Either the direct substrate
metabolite of the reaction of interest is 100% labeled and
the metabolite of interest is not a product from a conden-
sation reaction, or this is not the case. In the first case flux
can be calculated based on Eqn. (4) [51!!].
dXU
dt
¼ $ f X %
XU
XT
! "
(4)
Here, XU is the unlabeled metabolite level, fX is the sum
of fluxes producing the metabolite X from the tracer
substrate and XT is the total metabolite level (sum of
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all labeling states). Hence, XU/XT is the fraction of M+0 in
the metabolite of interest. In the second case isotopically
non-stationary 13C flux analysis [30!!,40,85!] or kinetic
flux profiling [51!!,90,91!!] can be performed. These
methods require the same additional data and information
as steady state 13C flux analysis and/or measurements of
metabolite levels along the pathway of interest. More-
over, to measure biosynthesis and turnover of polymers
mass isotopomer distribution analysis (MIDA) [92!] or
isotopomer spectral analysis (ISA) [93!] can be applied.
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Pyruvate anaplerosis is the counterpart to glutamine anaplerosis and allows the TCA cycle to continuosly oxidize acetyl-CoA simultaneously to provide carbon
backbones for biomass production. During pyruvate anaplerosis, pyruvate is converted via pyruvate carboxylase to oxaloacetate to compensate for metabolite loss
from TCA cycle due to biomass production.
Pyruvate anaplerosis can be identified by measuring M+3 malate, oxaloacetate, or fumarate under conditions when 13 C6-glucose is consumed (a). Notably,
oxaloacetate is not measurable by many metabolomics protocols because it requires a direct derivatization during quenching due to its chemical instability [96].
However, the labeling pattern of aspartate can serve as a surrogate of oxaloacetate labeling in aspartate-free medium, because if the medium does not contain
this amino acid, oxaloacetate is the sole source of aspartate carbon. Notably, if oxaloacetate from pyruvate anaplerosis is further used in the TCA cycle, also a
fraction of M+5 citrate from 13 C6-glucose will appear, because M+3 oxaloacetate will be combined with M+2 acetyl-CoA.
Under 13C6-glucose labeling conditions M+3 malate, aspartate, and fumarate can also be formed by multiple oxidation rounds in the TCA cycle (b). Hence, to
ensure that the M+3 malate, aspartate, and fumarate from 13C6-glucose are indicative of pyruvate anaplerosis, this isotopologue should be compared to the M+3
succinate (b). Comparison between malate, aspartate, and fumarate with succinate is thereby directly possible because they all consist of the same four-carbon
backbone. Thus, differences between the M+3 in malate, aspartate, and fumarate and the M+3 succinate represents the pyruvate anaplerosis contribution to the
TCA cycle, given that fumarate reductase activity is absent.
Fumarate reductase activity of the succinate dehydrogenase complex converts fumarate to succinate and thereby constitutes anaerobic electron transport. This
activity is found in many bacteria and fungi, but it has been also shown to occur in some mammalian cells during starvation, ischemic, or hypoxic conditions [97-
99]. When fumarate reductase activity is observed under 13C6-glucose labeling conditions, the M+3 malate, aspartate, and fumarate can match the M+3 succinate
although pyruvate anaplerosis is active (c). Therefore, the M+3 malate, aspartate, and fumarate should also be compared to the M+3 and M+4 a-ketoglutarate,
because the a-ketoglutarate to succinate reaction can be considered to operate only in forward direction (c). Notably, a-ketoglutarate consists of a five carbon
backbone and in the reaction to succinate CO2 is lost. Thus, this difference in the carbon backbone has to be taken into account when the MDVs of malate,
aspartate, and fumarate are compared to α-ketoglutarate.
To assess the contribution of pyruvate to TCA cycle via pyruvate carboxylase with an additional tracer, 1-13C1-pyruvate (or 3,4-13C2-glucose, which is converted to
1-13C1-pyruvate) can be used (d) [100,101]. Using these tracers, the 13C labeled carbon is lost in the pyruvate dehydrogenase reaction but is retained when
pyruvate enters via pyruvate anaplerosis into the TCA cycle (d). Any further TCA cycle metabolization of oxaloacetate from pyruvate anaplerosis, however, will lead
to loss of the the labeled carbon (d). Notably, when using a pyruvate tracer in the presence of glucose as a carbon source, the enrichment of 13C-pyruvate needs to
be taken into account when estimating relative pyruvate anaplerosis.
Hence, pyruvate anaplerosis is a good example that it can be helpful to depict not only the isotopologue of interest, but the MDVs of multiple connected
metabolites.
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Qualitative changes in pathway contribution: 13C tracer analysis to identify changes in pyruvate anaplerosis.
www.sciencedirect.com Current Opinion in Biotechnology 2015, 34:189–201
In some experimental setups, pragmatic simplifications to
compare flux between two conditions have been applied
[66,94,95]. For example, a pulse of a fully labeled carbon
source is added to the medium in a reference and in a
perturbed condition (e.g. mutant, or drug treatment).
Under the precondition that all metabolite levels along
the pathway of interest are lower in the perturbed condi-
tion than in the reference condition, a slower or equal
decrease in M+0 of the metabolite of interest in the
perturbed condition signifies a lower pathway flux in
the perturbed condition (Figure 2e). To allow assessment
of metabolite levels and labeling dynamics, both param-
eters should be depicted separately. Notably, such a
qualitative analysis of dynamic labeling data and metab-
olite levels are subject to the assumption that the non-
compartment specific metabolite level measurement
does not impact the data interpretation and that the
metabolites of the pathway of interest are not in rapid
exchange with other metabolites outside the pathway. If
doubts about these assumptions exist, then conclusions
based on the assumptions should be verified with formal
non-stationary 13C flux analysis.
Key aspects:
! Multiple time points are essential to interpret directly
dynamic 13C labeling patterns. Interpretations of single
time points of dynamic 13C labeling patterns are not
reliable.
! Dynamic labeling is limited by the feasible time
resolution (e.g. glycolytic intermediates are labeled in
the second to minute range).
! Qualitative and quantitative assessment of dynamic
labeling patterns (without formal non-stationary 13C
flux analysis) must take metabolite levels into account.
! Interpretation of labeling dynamics in a pathway with
metabolites that are in rapid exchange with other
metabolites outside a pathway require other
approaches than the here discussed direct 13C tracer
analysis.
! Compartment-dependent metabolite production can
impact the interpretation of dynamic labeling data.
Concluding remarks
13C-labeled and other isotope-labeled tracers can be
powerful tools to interrogate the metabolism of cells.
They can determine relative pathway activities, qualita-
tive changes in pathway contribution, nutrient contribu-
tions, and help infer metabolic fluxes. Analysis using more
than one tracer and examination of multiple metabolites
can help to increase the confidence in conclusions from
direct 13C tracer analysis. Moreover, integration of label-
ing data with additional information such as uptake and
secretion rates will increase the resulting understanding
of cellular metabolism and confidence in the biological
conclusions. Importantly, the biological question of
interest dictates which metabolic parameters (uptake
rates, relative pathway activities, pathway/nutrient con-
tributions, or fluxes) are most important to determine.
Taking into account the considerations discussed here
will hopefully be useful to the growing set of scientists
engaged in metabolic tracer studies.
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